289 related articles for article (PubMed ID: 26852660)
1. Immunophenotyping with CD135 and CD117 predicts the FLT3, IL-7R and TLX3 gene mutations in childhood T-cell acute leukemia.
Noronha EP; Andrade FG; Zampier C; de Andrade CF; Terra-Granado E; Pombo-de-Oliveira MS;
Blood Cells Mol Dis; 2016 Mar; 57():74-80. PubMed ID: 26852660
[TBL] [Abstract][Full Text] [Related]
2. Increased coexpression of c-KIT and FLT3 receptors on myeloblasts: independent predictor of poor outcome in pediatric acute myeloid leukemia.
Sharawat SK; Gupta R; Raina V; Kumar L; Sharma A; Iqbal S; Bakhshi R; Vishnubhatla S; Bakhshi S
Cytometry B Clin Cytom; 2013; 84(6):390-7. PubMed ID: 23740774
[TBL] [Abstract][Full Text] [Related]
3. CD117 expression is a sensitive but nonspecific predictor of FLT3 mutation in T acute lymphoblastic leukemia and T/myeloid acute leukemia.
Hoehn D; Medeiros LJ; Chen SS; Tian T; Jorgensen JL; Ahmed Y; Lin P
Am J Clin Pathol; 2012 Feb; 137(2):213-9. PubMed ID: 22261446
[TBL] [Abstract][Full Text] [Related]
4. Impact of FLT3 Receptor (CD135) Detection by Flow Cytometry on Clinical Outcome of Adult Acute Myeloid Leukemia Patients.
Kandeel EZ; El Sayed G; Elsharkawy N; Eldin DN; Nassar HR; Ibrahiem D; Amin R; Hanafi M; Khalil M; Kamel A
Clin Lymphoma Myeloma Leuk; 2018 Aug; 18(8):541-547. PubMed ID: 29907544
[TBL] [Abstract][Full Text] [Related]
5. Distinct immunophenotype of early T-cell progenitors in T lymphoblastic leukemia/lymphoma may predict FMS-like tyrosine kinase 3 mutations.
Zaremba CM; Oliver D; Cavalier M; Fuda F; Karandikar NJ; Chen W
Ann Diagn Pathol; 2012 Jan; 16(1):16-20. PubMed ID: 22050963
[TBL] [Abstract][Full Text] [Related]
6. FLT3-ITD and CD135 Over-Expression are Frequent Findings of Poor Survival in Adult Patients with Acute Leukemias.
Vela-Ojeda J; Cardenas PV; Garcia-Ruiz Esparza MA; Montiel Cervantes LA; Chavez JG; Caballero AH; Majluf-Cruz A; Vega-López A; Reyes-Maldonado E
Arch Med Res; 2021 Feb; 52(2):217-223. PubMed ID: 33109387
[TBL] [Abstract][Full Text] [Related]
7. [Detection of NPM1, FLT3 and C-KIT mutations in acute myeloid leukemia and their prognostic analysis].
Li L; Lyu XD; Mi RH; Ding J; Chen L; Wang Q; Yin QS; Hu JY; Fan RH; Wei XD
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Jun; 21(3):601-6. PubMed ID: 23815906
[TBL] [Abstract][Full Text] [Related]
8. Clinical features and outcome of SIL/TAL1-positive T-cell acute lymphoblastic leukemia in children and adolescents: a 10-year experience of the AIEOP group.
D'Angiò M; Valsecchi MG; Testi AM; Conter V; Nunes V; Parasole R; Colombini A; Santoro N; Varotto S; Caniglia M; Silvestri D; Consarino C; Levati L; Magrin E; Locatelli F; Basso G; Foà R; Biondi A; Cazzaniga G
Haematologica; 2015 Jan; 100(1):e10-3. PubMed ID: 25304610
[No Abstract] [Full Text] [Related]
9. Prognostic relevance of TLX3 (HOX11L2) expression in childhood T-cell acute lymphoblastic leukaemia treated with Berlin-Frankfurt-Münster (BFM) protocols containing early and late re-intensification elements.
Attarbaschi A; Pisecker M; Inthal A; Mann G; Janousek D; Dworzak M; Pötschger U; Ullmann R; Schrappe M; Gadner H; Haas OA; Panzer-Grümayer R; Strehl S;
Br J Haematol; 2010 Jan; 148(2):293-300. PubMed ID: 19821827
[TBL] [Abstract][Full Text] [Related]
10. Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia.
Zenatti PP; Ribeiro D; Li W; Zuurbier L; Silva MC; Paganin M; Tritapoe J; Hixon JA; Silveira AB; Cardoso BA; Sarmento LM; Correia N; Toribio ML; Kobarg J; Horstmann M; Pieters R; Brandalise SR; Ferrando AA; Meijerink JP; Durum SK; Yunes JA; Barata JT
Nat Genet; 2011 Sep; 43(10):932-9. PubMed ID: 21892159
[TBL] [Abstract][Full Text] [Related]
11. Disease Characteristics and Prognostic Implications of Cell-Surface FLT3 Receptor (CD135) Expression in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group.
Tarlock K; Alonzo TA; Loken MR; Gerbing RB; Ries RE; Aplenc R; Sung L; Raimondi SC; Hirsch BA; Kahwash SB; McKenney A; Kolb EA; Gamis AS; Meshinchi S
Clin Cancer Res; 2017 Jul; 23(14):3649-3656. PubMed ID: 28108543
[No Abstract] [Full Text] [Related]
12. Receptor kinase profiles identify a rationale for multitarget kinase inhibition in immature T-ALL.
Lhermitte L; Ben Abdelali R; Villarèse P; Bedjaoui N; Guillemot V; Trinquand A; Libura M; Bedin AS; Petit A; Dombret H; Leverger G; Ifrah N; Hermine O; Macintyre E; Asnafi V
Leukemia; 2013 Feb; 27(2):305-14. PubMed ID: 22751451
[TBL] [Abstract][Full Text] [Related]
13. Activating FLT3 mutations in CD117/KIT(+) T-cell acute lymphoblastic leukemias.
Paietta E; Ferrando AA; Neuberg D; Bennett JM; Racevskis J; Lazarus H; Dewald G; Rowe JM; Wiernik PH; Tallman MS; Look AT
Blood; 2004 Jul; 104(2):558-60. PubMed ID: 15044257
[TBL] [Abstract][Full Text] [Related]
14. T-lymphoid/myeloid mixed phenotype acute leukemia and early T-cell precursor lymphoblastic leukemia similarities with
Noronha EP; Marques LVC; Andrade FG; Sardou-Cezar I; Dos Santos-Bueno FV; Zampier CDP; Terra-Granado E; Pombo-de-Oliveira MS
Cancer Manag Res; 2019; 11():3933-3943. PubMed ID: 31118806
[No Abstract] [Full Text] [Related]
15. FLT3 mutations in early T-cell precursor ALL characterize a stem cell like leukemia and imply the clinical use of tyrosine kinase inhibitors.
Neumann M; Coskun E; Fransecky L; Mochmann LH; Bartram I; Sartangi NF; Heesch S; Gökbuget N; Schwartz S; Brandts C; Schlee C; Haas R; Dührsen U; Griesshammer M; Döhner H; Ehninger G; Burmeister T; Blau O; Thiel E; Hoelzer D; Hofmann WK; Baldus CD
PLoS One; 2013; 8(1):e53190. PubMed ID: 23359050
[TBL] [Abstract][Full Text] [Related]
16. The importance of relative mutant level for evaluating impact on outcome of KIT, FLT3 and CBL mutations in core-binding factor acute myeloid leukemia.
Allen C; Hills RK; Lamb K; Evans C; Tinsley S; Sellar R; O'Brien M; Yin JL; Burnett AK; Linch DC; Gale RE
Leukemia; 2013 Sep; 27(9):1891-901. PubMed ID: 23783394
[TBL] [Abstract][Full Text] [Related]
17. FLT3-TKD mutation in childhood acute myeloid leukemia.
Liang DC; Shih LY; Hung IJ; Yang CP; Chen SH; Jaing TH; Liu HC; Wang LY; Chang WH
Leukemia; 2003 May; 17(5):883-6. PubMed ID: 12750701
[TBL] [Abstract][Full Text] [Related]
18. Risk assessment in patients with acute myeloid leukemia and a normal karyotype.
Bienz M; Ludwig M; Leibundgut EO; Mueller BU; Ratschiller D; Solenthaler M; Fey MF; Pabst T
Clin Cancer Res; 2005 Feb; 11(4):1416-24. PubMed ID: 15746041
[TBL] [Abstract][Full Text] [Related]
19. Internal tandem duplication of the FLT3 gene confers poor overall survival in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based chemotherapy: an International Consortium on Acute Promyelocytic Leukemia study.
Lucena-Araujo AR; Kim HT; Jacomo RH; Melo RA; Bittencourt R; Pasquini R; Pagnano K; Fagundes EM; Chauffaille Mde L; Chiattone CS; Lima AS; Ruiz-Argüelles G; Undurraga MS; Martinez L; Kwaan HC; Gallagher R; Niemeyer CM; Schrier SL; Tallman MS; Grimwade D; Ganser A; Berliner N; Ribeiro RC; Lo-Coco F; Löwenberg B; Sanz MA; Rego EM
Ann Hematol; 2014 Dec; 93(12):2001-10. PubMed ID: 24981688
[TBL] [Abstract][Full Text] [Related]
20. BCL11B, FLT3, NOTCH1 and FBXW7 mutation status in T-cell acute lymphoblastic leukemia patients.
Kraszewska MD; Dawidowska M; Kosmalska M; Sędek L; Grzeszczak W; Kowalczyk JR; Szczepański T; Witt M;
Blood Cells Mol Dis; 2013 Jan; 50(1):33-8. PubMed ID: 23040356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]